IMSA-101 is under clinical development by ImmuneSensor Therapeutics and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II drugs for Metastatic Melanoma have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMSA-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMSA-101 overview
IMSA-101 is under development for the treatment of advanced or metastatic solid tumors including malignant melanoma, hormone receptor negative breast cancer, gastro-esophageal cancer, non small cell lung cancer, uveal myeloma, head and neck cancer, hepatoma and renal cell carcinoma, hematologic malignancies and refractory malignancies. It is administered intratumorally. It acts by targeting STING.
It was under development for non small cell lung cancer, renal cell carcinoma and TNBC.
ImmuneSensor Therapeutics overview
ImmuneSensor Therapeutics is a clinical stage biopharmaceutical company that develops novel treatments that address both cancers and autoimmune diseases. The company is headquartered in Dallas, Texas, the US.
For a complete picture of IMSA-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
